BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 12077315)

  • 1. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
    Westervelt P; Pollock JL; Oldfather KM; Walter MJ; Ma MK; Williams A; DiPersio JF; Ley TJ
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9468-73. PubMed ID: 12077315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.
    Ozpolat B; Lopez-Berestein G
    Leuk Lymphoma; 2002 May; 43(5):933-41. PubMed ID: 12148903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
    Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide, a therapeutic agent for APL.
    Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
    Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
    Chen Z; Wang ZY; Chen SJ
    Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
    Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
    Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
    Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
    Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
    Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment concepts of acute promyelocytic leukemia.
    Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid.
    Douer D; Estey E; Santillana S; Bennett JM; Lopez-Bernstein G; Boehm K; Williams T
    Blood; 2001 Jan; 97(1):73-80. PubMed ID: 11133744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
    Calleja EM; Warrell RP
    Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in therapies for acute promyelocytic leukemia.
    Kamimura T; Miyamoto T; Harada M; Akashi K
    Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.